Pharmaceuticals
-
Lubrizol targets drug delivery challenges at CPHI Milan
At CPHI Milan (6–8 Oct 2026), Lubrizol will spotlight multifunctional excipients at stand 1F40—showing how Apisolex boosts API solubility up to 50,000-fold with high loading, and how Apinovex supports oral forms—to elevate formulation performance, patient experience, and product differentiation.
-
Future-proofing pharma QC: Navigating regulations and testing in 2026
Future‑proof your QC in 2026 with advanced analytics, robust validation, and ALCOA+ data integrity. Learn how to meet tougher FDA/EMA/ICH expectations, modernise lab workflows, and turn digital evidence into faster, cleaner approvals—powered by practical insights and Labotec solutions.
-
South Africa API Innovation Cluster Phase 2 launch
South Africa has launched Phase 2 of the CSIR-led API Innovation Cluster, backed by DSTI and TIA, to cut medicine imports and boost local resilience. Discover how a national network and CSIR’s FuturePHARMA and CPT Pharma API+ labs will speed small‑molecule APIs from lab to market.
-
Once-monthly oral HIV PrEP: MSD partners with Aspen for LMIC access
MSD has tapped South Africa’s Aspen to help deliver alimatravir, an investigational once‑monthly oral HIV PrEP, via royalty‑free, non‑exclusive licenses across 129 low‑ and middle‑income countries—pending trials and approvals. With 1.2m new infections in 2025 and PrEP uptake lagging, see how access could scale fast.
-
Africa’s first end-to-end mRNA facility secures SAHPRA approval
Afrigen Biologics has secured SAHPRA GMP certification for its Cape Town mRNA facility—the first end-to-end site in Africa authorised to manufacture investigational biologicals for Phase I/II trials. Discover how this milestone strengthens supply security, pandemic readiness and the WHO-MPP mRNA network.
-
Unregistered Semaglutide Tirzepatide recall: SAHPRA & SAPC seize products at Sentra Pharmacy
SAHPRA and the SAPC raided Sentra Pharmacy (Silverton, Pretoria) on 11 May 2026, seizing unregistered Semaglutide, Tirzepatide and combo GLP‑1/GIP injectables amid illegal API imports, poor sterility and no pharmacovigilance. See the enforcement steps, recall scope and risks for patients and prescribers.
-
Cleanroom solutions Africa: Turnkey expertise by AFMS
AFMS, based in Midrand, South Africa, has been a trusted provider of cleanroom and containment solutions for over 40 years. Specialising in modular, mobile, and permanent facilities, AFMS delivers turnkey solutions across Africa and beyond.
-
Introducing the Glatt GSX pharma spray dryer
Meet the Glatt GSX pharma spray dryer—built with pharmacists for pharmacists—to deliver GMP-ready design, OEB 5 containment, and reproducible scale-up. Explore how its advanced particle engineering and 21 CFR Part 11 digital control enable precise micro/nano particles, amorphous solid dispersions, and lipid-based delivery for faster, compliant tech transfer.
-
Evonik Slovakia biotechnology expansion: €80 mn investment
Evonik will introduce advanced downstream fermentation technology, enhancing the group’s drug-substance contract manufacturing capabilities. The project is expected to create around 50 new jobs, further boosting the local economy.
-
Beauty brands cross into pharmacy territory: SAPHEX signals market shift
At SAPHEX, beauty brands moved firmly into pharmacy aisles—chasing dermocosmetics, prevention-first care, and masstige shoppers as pharmacies evolve into health hubs. See how players like Nativechild are reshaping hair and body care with science-backed, locally made solutions—and what this retail shift means for your brand.
-
Manuchar to acquire CJP Chemicals in South Africa
Manuchar will acquire South Africa’s CJP Chemicals, expanding its reach across personal care, pharmaceuticals, food and beverage, and industry, pending antitrust approval for a planned Q3 2026 close. See how this deal links a $2.6bn distributor with a $100m local leader operating in Johannesburg, Durban, Cape Town and Gqeberha.
-
Ingredient-led skincare in SA: A growing trend
South African shoppers are flipping bottles for glycolic, niacinamide and retinol—not promises. Explore how ingredient-led skincare is reshaping demand, what consumers really want, and where the retail wins are, with insights from RTSC’s general manager, Nick Hunt.
